This week, we’re sharing the most recent top stories in dermatology news.
A new study finds psoriasis is associated with an elevated risk of COVID-19. In other news, three new studies show drug efficacy in psoriasis, resected melanoma, and chronic hand eczema.
Read more on these stories below:
Psoriasis Associated With an Increased Risk for COVID-19 in Real-World Study Medscape, April 28, 2021
In the study, some systemic treatments appeared to lower risk in patients, compared with those on topical therapy.
Meet Muneeb Shah, the dermatology resident with 6 million TikTok followers Glossy, April 23, 2021
Dermatology is one of the subjects that has been embraced by the platform with posts from clinicians gaining traction and being widely shared.
Psoriasis Clearance Rates Higher With Bimekizumab vs Secukinumab Medscape, April 28, 2021
At 4 months, 61.7% of those on bimekizumab vs 48.9% on secukinumab, had complete clearance with a PASI score of 100.
Nivolumab Alone Prevails in Resected Melanoma Medpage Today, April 11, 2021
Dual checkpoint blockade with nivolumab (Opdivo) plus ipilimumab (Yervoy) failed to improve outcomes as adjuvant therapy for resected melanoma over nivolumab alone.
Rapid, substantial improvements seen with gusacitinib for chronic hand eczema Healio, May 6, 2021
Gusacitinib produced significant and rapid improvement of severity and pain in patients with moderate to severe chronic hand eczema.